Navigation Links
Amilpar - Relevant Fact - Public Offer
Date:12/9/2009

RIO DE JANEIRO, Dec. 9 /PRNewswire-FirstCall/ -- Amilpar (Bovespa: AMIL3; Bloomberg: AMIL3 BZ and APAR < GO >; Reuters: AMIL3.SA), the largest managed care organization in Brazil, in addition to the Relevant Facts released on November 19, 2009 and December 2, 2009, informs its shareholders and the market that the initiatives to proceed with the Public Offer defined below were started today, having as Applicant its subsidiary AMIL ASSISTENCIA MEDICA INTERNACIONAL LTDA. The filing to register the public offer for the acquisition of shares issued by Medial Saude S.A. ("Medial") due to the control change, at the price of R$ 17.2066 per share, along with the exit from Novo Mercado and delisting of the company was done at CVM - Comissao de Valores Mobiliarios (Brazilian Securities and Exchange Commission), according to article 254-A of Law 6,404/76, CVM Instruction 361/02, BM&FBovespa's Novo Mercado Regulation and the Bylaws of Medial Saude S.A. ("Public Offer").

Amilpar informs that Medial's economic value per share is subject to confirmation through the valuation report to be prepared according to BM&FBovespa's Novo Mercado rules.

Amilpar will keep the market and its shareholders informed about the conclusion of the above-mentioned offer.

    To access the Relevant Fact, visit our website at www.amilpar.com.br/ir

    IR Contact
    Erwin Kleuser
    Investor Relations Officer
    Phone: +55 (21) 3805-1155
    invest@amil.com.br
    www.amilpar.com.br/ir

SOURCE Amilpar


'/>"/>
SOURCE Amilpar
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Amilpar - Revenues Grow 8% and Net Income Improves 28% in 3Q09
2. Amilpar - Operating Revenues Grew 9% in the Second Quarter and 11% in the First Half of 2009
3. Amilpar - Revenue Increases 13.4% and Medical Loss Ratio Falls in the First Quarter 2009
4. Amilpar - Revenues Increase by 26.5% and Adjusted Net Income Climbs 28.7% in 2008
5. Amilpar - Notice to Shareholders - Distribution of Interest on Capital Stock
6. Amilpar Revenues Grow 28% in the First 9 Months of 2008 and 4.5% Over Previous Quarter
7. Amilpar Revenues Increase by 32% and EBITDA Doubles in 2007
8. Healthcare Organizations Face Tough Marketing Challenges - GY&K Asks Are You Relevant?
9. Relevant Security and bitRail Debut RevSecure Product Line
10. 30th Anniversary Edition of Mandell, Douglas, and Bennetts Principles and Practice of Infectious Diseases is More Relevant Than Ever
11. www.greatplacesinc.com Isthe Leading Internet Resourcefor Current, Relevant, Reliable Advice,Counseling the 76 MillionBaby Boomers Who Are Increasingly Responsible for Their Aging Parents' Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... 24, 2017 , ... Gastro Health (“GH”) ( http://www.gastrohealth.com ... for colonoscopy at the HyGIeaCare® Center that is to be located adjacent to ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration (FDA), ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate about ... what is often a very difficult and challenging time.” , A Certified Medical ...
(Date:3/24/2017)... ... ... Time GPS”: a dauntless and enlightened study of the second-coming of Christ, and ... published author, Wesley Gerboth, a World War II veteran, with a highly-regarded reputation as ... ninety-one, he shares the Wisdom God bestowed upon him in this publication. , ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... collection of inspiring stories about real people of God in congregations across the ... John Miller, a Presbyterian minister ordained in 1964 who has served congregations in ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health ... there could be four million Zika-related cases in the Americas within the next year. ... US cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 24, 2017 A ReportsnReports.com report ... been growing rapidly as the global sales of Adcetris and Kadcyla ... in the antibody drug conjugates market is driven by large number ... and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 ...
(Date:3/24/2017)...  GenomeDx Biosciences today announced that six abstracts featuring ... Cancer Classifier tests will be presented at the 32 ... held March 24 to 28, 2017 in ... Europe,s largest urological event showcasing ... field. The abstract titled "Muscle invasive bladder ...
(Date:3/24/2017)... 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... oncology and dermatology biopharmaceutical company, today disclosed terms ... Sheet (the "Definitive Financing") it entered into on ... stockholders, who are referred to in the Definitive ... filed with the Securities and Exchange Commission.   ...
Breaking Medicine Technology: